Pfizer's elranatamab meets Phase III primary endpoint in relapsed or refractory multiple myeloma

Pfizer (NYSE: PFE) reported that elranatamab (Elrexfio) met its primary endpoint in the Phase III MagnetisMM-5 trial, demonstrating a statistically significant improvement in progression-free survival versus standard-of-care daratumumab plus pomalidomide and dexamethasone in patients with relapsed or refractory multiple myeloma who had received at least one prior line of therapy. The readout positions Elrexfio as a potential earlier-line option in a disease where most patients cycle through multiple regimens before exhausting available treatments.

The MagnetisMM-5 trial is an open-label, multicenter, randomized Phase III study that enrolled 497 patients across 26 countries with relapsed or refractory multiple myeloma who had previously received lenalidomide and a proteasome inhibitor.

Pfizer disclosed that PFS, assessed by blinded independent central review, exceeded the pre-specified interim hazard ratio threshold for efficacy, with most elranatamab-treated patients remaining progression-free at the time of the analysis. The company did not release a numerical hazard ratio, median PFS values, or response rates in the topline announcement, describing the improvement as clinically meaningful without quantifying the magnitude. Overall survival, a key secondary endpoint, was not yet mature and the trial continues. Safety was consistent with the established elranatamab profile, with no new signals identified.

The context for these results matters. Elrexfio currently carries US FDA accelerated approval for adults with RRMM who have received at least four prior lines of therapy, including a proteasome inhibitor, an immunomodulatory agent, and an anti-CD38 monoclonal antibody. In the EU, conditional marketing authorization covers patients after at least three prior therapies. MagnetisMM-5 enrolled patients after as few as one prior line, meaning a positive outcome here could support a substantially earlier label, broadening the eligible population considerably.

Elranatamab is a subcutaneously delivered bispecific antibody that binds B-cell maturation antigen on myeloma cells and CD3 on T cells, redirecting cytotoxic T cells to kill BCMA-expressing tumor cells. The mechanism is shared by two other approved agents in the class: teclistamab (Tecvayli), which received FDA accelerated approval in October 2022, and linvoseltamab (Lynozyfic), approved by the FDA in July 2025. All three are BCMA×CD3 bispecifics administered on step-up dosing schedules designed to mitigate cytokine release syndrome, the class's most clinically prominent toxicity. Cross-trial comparisons are limited by differences in patient populations, prior therapy requirements, and trial designs, meaning the MagnetisMM-5 data cannot be directly interpreted as evidence of superiority over teclistamab or linvoseltamab.

What distinguishes the MagnetisMM-5 readout from earlier elranatamab data is the comparator and the line of therapy. The trial tested elranatamab against daratumumab plus pomalidomide and dexamethasone, a widely used standard-of-care regimen in second- and later-line RRMM, rather than against a historical benchmark or placebo. A randomized Phase III win against an active comparator in earlier-line disease carries different regulatory weight than the single-arm data that supported the current accelerated approval. Pfizer said it plans to discuss the results with global health authorities, and that detailed data will be submitted for presentation at a future medical congress, meaning the numerical readout remains pending.

The broader MagnetisMM program reflects a strategy of testing elranatamab across lines of therapy and in combination. The fully recruited Phase III MagnetisMM-32 study is evaluating elranatamab in patients who previously received daratumumab as part of front-line treatment, a population increasingly common as daratumumab-based induction has become standard practice. That study addresses a practical clinical question: what to offer patients who are already CD38-antibody exposed when they relapse, a group for whom the DPd comparator used in MagnetisMM-5 would not be appropriate.

The double-class exposed myeloma population that MagnetisMM-5 targets sits at a juncture where treatment decisions are becoming more complex. As daratumumab moves earlier into front-line regimens, the proportion of patients who are CD38-refractory at first relapse is growing, limiting the utility of daratumumab-containing salvage options. BCMA-directed bispecifics and CAR T-cell therapies — including ciltacabtagene autoleucel (Carvykti) and idecabtagene vicleucel (Abecma) — have expanded options in later lines, but access to cellular therapies remains constrained by manufacturing timelines and specialized center requirements. An off-the-shelf subcutaneous bispecific with a randomized Phase III PFS benefit in earlier disease could occupy a distinct niche, though the absence of numerical data makes any such positioning premature.

---

This article was generated with AI assistance and reviewed and edited by the AllSci editorial team Explore more at AllSci News: https://allsci.com/news/

---

Spot something wrong? Report an issue with this article